CytoRad dispute lowers Cytogen revenues
Monoclonal antibody developer Cytogen reported a sharp drop in its 1994 revenues as a resultof its dispute last year with sister company CytoRad. Cytogen,of Princeton, NJ, had total revenues for 1994 (end-December) of$2.5 million, down from $10.4 million
Monoclonal antibody developer Cytogen reported a sharp drop in its 1994 revenues as a resultof its dispute last year with sister company CytoRad. Cytogen,of Princeton, NJ, had total revenues for 1994 (end-December) of$2.5 million, down from $10.4 million in 1993. Cytogen's net lossfor the year was $32.8 million, compared to a net loss of $29.2million a year ago.
The revenue shortfall was caused by the absence of contractrevenue from CytoRad, which had contributed $7.9 million to Cytogen'sbalance sheet in 1993. CytoRad, formed to fund R&D at Cytogen,cut off its contributions last year after a dispute over theirbusiness relationship (SCAN 6/29/94 and 4/20/94).
Cytogen is hoping to put the CytoRad affair behind it by acquiringthat company, and Cytogen reported that its stockholders approvedthe acquisition at a special meeting held on Feb. 23.
Outside of the CytoRad shortfall, Cytogen's 1994 numbers painteda picture of a company that is cutting operating expenses andexperiencing increased sales of its OncoScint CR/OV monoclonalantibody imaging agent. OncoScint product sales for the fourthquarter of 1994 were $480,000 compared to $259,000 in the sameperiod a year ago. Cytogen cut operating expenses 16% comparedto the year before. The company recorded a charge of $4.1 millionin the fourth quarter in connection with the CytoRad acquisitionas well as its reacquisition of OncoScint marketing rights fromKnoll Pharmaceutical.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
